naxitamab + sargramostim + isotretinoin

This is a **combination regimen** comprising naxitamab, sargramostim, and isotretinoin, primarily investigated for **maintenance therapy and post-consolidation treatment** in patients with **high-risk neuroblastoma**, particularly in first complete response or in relapsed/refractory cases[6]. Naxitamab is a **humanized monoclonal antibody** targeting disialoganglioside **GD2**, highly expressed in neuroblastoma cells, leading to immune-mediated cytotoxicity. **Sargramostim** (GM-CSF) is a recombinant human granulocyte-macrophage colony-stimulating factor that enhances immune effector cell activation, especially granulocytes and macrophages, facilitating antibody-dependent cellular cytotoxicity[7]. **Isotretinoin** is a retinoid (vitamin A derivative) that induces differentiation and apoptosis in neuroblastoma cells, used as a maintenance agent after intensive therapy[7]. The regimen is established in clinical trials for improving event-free and overall survival in neuroblastoma patients and is administered as cyclic intravenous (naxitamab) and subcutaneous (sargramostim) infusions, combined with oral isotretinoin[6][1][3][7].

Brand names

Danyelza (naxitamab)Leukine (sargramostim)Accutane (isotretinoin)

Other names

GM-CSF (sargramostim)13-cis-retinoic acid (isotretinoin)